ACD PHARMACEUTICALS AS: årsregnskap 2025 vs 2024
Weaker earnings, fresh owner capital
approved 2026-06-30; registry 2026-08-15; journal 2026 725727
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for ACD PHARMACEUTICALS AS. Revenue 24.67m NOK → 25.63m NOK (+3.9%). Net result -967.1k NOK → -1.92m NOK.
On the constructive side: revenue rose; operating result improved; cash rose. Pressures included: net result weakened.
Also worth watching: cogs fell; headcount (årsverk) changed. All figures are taken from the published annual accounts for ACD PHARMACEUTICALS AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 24.67m NOK to 25.63m NOK (+3.9% YoY). Calculated
-
↑
Operating result improved
Operating result -3.82m NOK → -2.53m NOK (op. margin -15.5% → -9.9%). Calculated
-
↑
Cash rose
Bank deposits 19.3k NOK → 41.76m NOK (+215812.6% YoY). Calculated
-
↑
Current ratio back above 1×
Current ratio 0.44× → 2.71×. Calculated
-
↑
Owners injected capital
Paid-in equity rose 13.39m NOK → 55.72m NOK (+42.33m NOK). Reported fact
What deteriorated
-
↓
Net result weakened
Net result -967.1k NOK → -1.92m NOK (net margin -3.9% → -7.5%). Calculated
Things to notice
-
·
COGS fell
COGS / varekostnad 8.30m NOK → 4.72m NOK (-43.1% YoY). Calculated
-
·
Headcount (årsverk) changed
Reported FTEs 7.5 → 10.3. Reported fact